EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange Boca Raton, Fla. - July 31, 2026 - NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), a leader in transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that the Company’s common stock is now available for options trading on the Cboe Options Exchange under the symbol “NMAD.” “The launch of options trading on NOMAD’s stock represents a meaningful step in the continued development of our public markets profile,” said Geordan Pursglove, Chief Executive Officer of NOMAD. “Alongside our Nasdaq listing, we believe it can increase visibility among both institutional and retail investors and help strengthen the trading ecosystem around NOMAD as we continue advancing our mission to deliver flexible energy storage solutions to utilities, AI and hyperscale data centers, and a broad range of other commercial and industrial customers.” The company’s common stock will continue to trade on the Nasdaq Stock Market under its current ticker symbol, NMAD. Trading…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
NOMAD POWER SOLUTIONS, INC.
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 31, 2026, Nomad Power Solutions, Inc., (the “Company”), issued a press release announcing that the Company’s common stock is now available for options trading on the Cboe Options Exchange under the symbol “NMAD.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.…
Company context
We are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. Our product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.
Recent company filings
- Regulation FD DisclosureOct 6, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 30, 2026
- Financial Statements and ExhibitsSep 17, 2026
- 10-Q filingAug 14, 2026
- SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding NOMAD POWER SOLUTIONS, INC.Jul 31, 2026